Drugs that contain Infigratinib Phosphate
1. Drug name - TRUSELTIQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(5 years from now) | |
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(6 years from now) | |
| CN101035769A | HELSINN HLTHCARE | Pyrimidine Carbamide Ramification Used As Kinase Inhibitor |
Aug, 2013
(9 years ago) | |
| CN102639510A | HELSINN HLTHCARE | 3-(2, 6--3, 5-Dimethoxy-Phenyl)--1-{6-[4-(4-Ethyl-Piperazin--1-Yl)-Phenyl Amino]-Pyrimidin--4-Yl}--1-Methyl-Urea And Their Salt Form |
Apr, 2016
(6 years ago) | |
| CN103121972B | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| CN103121972A | HELSINN HLTHCARE | Pyridine Urea Derivatives As Kinase Inhibitor |
Jun, 2025
(2 years from now) | |
| IN200606843P1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| IN261843B | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP1761505B1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP2418205A1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP1761505A1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP2409969A1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP2418205B1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP2409969B1 | HELSINN HLTHCARE | Pyrimidine Urea Derivatives As Kinase Inhibitors |
Jun, 2025
(2 years from now) | |
| EP2509963B1 | HELSINN HLTHCARE | Crystalline Forms Of 3-(2,6-Dichloro-3,5-Dimethoxy-Phenyl)-1-{6-[4-(4-Ethyl-Piperazin-1-Yl)-Phenylamino]-Pyrimidin-4-Yl}-1-Methyl-Urea And Salts Thereof. |
Dec, 2030
(8 years from now) | |
| EP2509963A1 | HELSINN HLTHCARE | Crystalline Forms Of 3-(2,6-Dichloro-3,5-Dimethoxy-Phenyl)-1-{6-[4-(4-Ethyl-Piperazin-1-Yl)-Phenylamino]-Pyrimidin-4-Yl}-1-Methyl-Urea And Salts Thereof. |
Dec, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(12 years from now) | |
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(12 years from now) | |
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 25MG | CAPSULE;ORAL | Prescription |
| 100MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.